| Literature DB >> 32339832 |
Biswaranjan Paital1, Kabita Das2, Sarat Kumar Parida3.
Abstract
Infection by coronavirus (CoV-19) has led to emergence of a pandemic called as Coronavirus Disease (COVID-19) that has so far affected about 210 countries. The dynamic data indicate that the pandemic by CoV-19 so far has infected 2,403,963 individuals, and among these 624,698 have recovered while, it has been fatal for 165,229. Without much experience, currently, the medicines that are clinically being evaluated for COVID-19 include chloroquine, hydroxychloroquine, azithromycin, tocilizumab, lopinavir, ritonavir, tocilizumab and corticosteroids. Therefore, countries such as Italy, USA, Spain and France with the most advanced health care system are partially successful to control CoV-19 infection. India being the 2nd largest populous country, where, the healthcare system is underdeveloped, major portion of population follow unhygienic lifestyle, is able to restrict the rate of both infection and death of its citizens from COVID-19. India has followed an early and a very strict social distancing by lockdown and has issued advisory to clean hands regularly by soap and/or by alcohol based sterilizers. Rolling data on the global index of the CoV infection is 13,306, and the index of some countries such as USA (66,148), Italy (175,055), Spain (210,126), France (83,363) and Switzerland (262,122) is high. The index of India has remained very low (161) so far, mainly due to early implementation of social lockdown, social distancing, and sanitizing hands. However, articles on social lockdown as a preventive measure against COVID-19 in PubMed are scanty. It has been observed that social lockdown has also drastic impacts on the environment especially on reduction of NO2 and CO2 emission. Slow infection rate under strict social distancing will offer time to researchers to come up with exact medicines/vaccines against CoV-19. Therefore, it is concluded that stringent social distancing via lockdown is highly important to control COVID-19 and also to contribute for self-regeneration of nature.Entities:
Keywords: COVID-19; Clinical management; Environmental effect; Pandemic; Social distancing; Social lockdown
Mesh:
Year: 2020 PMID: 32339832 PMCID: PMC7179495 DOI: 10.1016/j.scitotenv.2020.138914
Source DB: PubMed Journal: Sci Total Environ ISSN: 0048-9697 Impact factor: 7.963
Fig. 1Confirmed cases of COVID 19 positive cases worldwide. The intensity of color indicates number of affected people per 1 million people in world as of now on 02.04.2020 (Source https://google.com/covid19-map/?hl=en), b.-numerical values for the total number of cases in C-19 as on 04.03.2020.
FDA and WHO recommended drugs for the treatment of COVID-19.
| Name of drug | Working root | Risk Factors | Overall efficacy |
|---|---|---|---|
| Chloroquine | In vitro activity against SARS-CoV-2 and may have immunomodulating properties. Inhibition of viral enzymes or processes such as viral DNA and RNA polymerase, viral protein glycosylation, virus assembly, new virus particle transport, and virus release. ACE2 cellular receptor inhibition, acidification at the surface of the cell membrane inhibiting fusion of the virus, and immunomodulation of cytokine release. | Risk of cardiac arrhythmias (e.g., QT prolongation) Risk of retinal damage, especially with long term use Caution in patients with G6PD deficiency Caution in diabetics Significant drug interactions | In vitro and limited clinical data suggest potential benefit. |
| Hydroxychloroquine | Same as above | Same as above | Same as above |
| Lopinavir; Ritonavir | In vitro and animal model studies show potential activity for other coronaviruses (SARS-CoV and MERS-CoV). | Risk of cardiac arrhythmias (e.g., QT prolongation) Caution in patients with hepatic disease or hepatitis Significant drug interactions | Role in the treatment of COVID-19 is unclear. Preclinical data suggested potential benefit; however, more recent data has failed to confirm. |
| Remdesivir | Act as a broad-spectrum antiviral with in vitro activity against coronaviruses. Acts as an inhibitor of RNA-dependent RNA polymerases (RdRps). Remdesivir-TP competes with adenosine-triphosphate for incorporation into nascent viral RNA chains. Once incorporated into the viral RNA at position i, RDV-TP terminates RNA synthesis at position i + 3. Because RDV-TP does not cause immediate chain termination (i.e., 3 additional nucleotides are incorporated after RDV-TP), the drug appears to evade proofreading by viral exoribonuclease (an enzyme thought to excise nucleotide analog inhibitors). | – | Investigational and available only through expanded access and study protocols; several large clinical trials are underway. |
| Azithromycin | It may prevent bacterial superinfection, and macrolides may have immunomodulatory properties to work as adjunct therapy. It may have immunomodulatory properties in pulmonary inflammatory disorders. They may downregulate inflammatory responses and reduce the excessive cytokine production associated with respiratory viral infections; however, their direct effects on viral clearance are uncertain. Immunomodulatory mechanisms may include reducing chemotaxis of neutrophils (PMNs) to the lungs by inhibiting cytokines (i.e., IL-8), inhibition of mucus hypersecretion, decreased production of reactive oxygen species, accelerating neutrophil apoptosis, and blocking the activation of nuclear transcription factors. | Risk of cardiac arrhythmias (e.g., QT prolongation) Significant drug interactions | Used in some protocols based on theoretical mechanism and limited preliminary data as adjunct therapy. |
| Tocilizumab | Cytokine release syndrome may be a component of severe disease in COVID-19 patients. Inhibits IL-6-mediated signaling by competitively binding to both soluble and membrane-bound IL-6 receptors. IL-6 is a proinflammatory cytokine that is involved in diverse physiological processes such as T-cell activation, immunoglobulin secretion induction, hepatic acute-phase protein synthesis initiation, and hematopoietic precursor cell proliferation and differentiation stimulation. IL-6 is produced by various cell types, including T- and B-cells, lymphocytes, monocytes, and fibroblasts. | Risk of GI perforation Risk of hepatotoxicity Caution in patients with thrombocytopenia and neutropenia Infusion-related reactions | Immunomodulating agent used in some protocols based on theoretical mechanism and limited preliminary data as adjunct therapy. |
| COVID-19 convalescent plasma | Clinical trials are being conducted to evaluate the use of COVID-19 convalescent plasma to treat patients with severe or immediately life-threatening COVID-19 infections. COVID-19 convalescent plasma is not intended for prevention of the infection. | Awaiting as clinical trials are on it are going on. | Investigational use is being studied. |
| Corticosteroid therapy | Corticosteroid therapy is not recommended for viral pneumonia; however, use may be considered for patients with refractory shock or acute respiratory distress syndrome. | Normal corticosteroid administration issues along with cardiac arrest problem. | Not recommended for viral pneumonia; however, use may be considered for patients with refractory shock or acute respiratory distress syndrome. |
The table is prepared after Smith et al. (2020), an open access article with common creative attribution.
Fig. 2A typical figure of COVID-19. White arrows indicate its receptors protein on its surface and the red arrows indicate the envelop protein. b) A single stranded RNA is enclosed by envelop protein layer (modified after Scripps Research Institute (89)).
Fig. 3Death rate of patients as a function of age. Analyses of the data till 05.04.2020 indicates that elderly patients are with a high risk of death under COVID-19 infection, while, young and children are not totally safe (CDC, 2020).
Fig. 4Number of beds available nation wise in respective years. India lags behind the far in the list and joins among counties such as Afghanistan, Bangladesh, Cambodia, Ethiopia, Ghana, Guinea, Madagaskar, Mozambique, Nigeria, Pakistan, Sudan, Uganda and Yemen. Data are as per the latest updates on 06.04. 2002 in Word Bank website.
Fig. 5Status of COVID-19 pandemic in India (Data obtained from the Ministry of Health & Family Welfare, Government of India, New Delhi). a) Although the first positive case was started in 1st January 2020, the rate of increase of the pandemic was not that much high I comparison to the other developed counties. The number of confirmed cases has gained a sharp increase from 9th March 2020 to 5th April 2020, but the number remained within hundreds up to 28th March and with 4000 up to 5th April 2020. It shows a great control over the disease. Similarly, recoveries and death rate were very slow limiting within 100, indicating a positive aspect in favor of control of the disease. b) The percentage of increase of the infection, recoveries death case was very slow and the graph have showed different spikes but overall a steady stable growth indicating a strong grip of the federal government of India over the diseases.
Fig. 6Major economic associated change in three main cities of India. Data are as per the daily foot prints in terms of walk-ins from Goole India data (in first week of lockdown) to the respective sectors in first week of lockdown. The average changeover of foot prints (%) are represented in Delhi, Mumbai, Bengaluru and Chennai for a) banking and petrol pump sector, b) grocery shops and in c)diagnostic centres (sources Livemint (60)). Reproduced under a creative commons license (60).
Fig. 7Propagation of CoV-19 in host cells via S protein that binds ACE2.
a)After S binds to ACE2, the conformation change in the S protein to cleave it into S1 and S2 proteins that facilitates viral envelope fusion with the cell membrane through the endosomal pathway. Then CoV-19 releases RNA into the host cell and its RNA is translated into viral replicase polyproteins pp1a and 1ab, which are then cleaved into small products by viral proteinases. The polymerase produces a series of sub-genomic mRNAs by discontinuous transcription and at the end, translated into relevant viral proteins. Viral proteins and genome RNA are subsequently assembled into virions in the ER and Golgi and then transported via vesicles and released out of the cell. ACE2, angiotensin-converting enzyme 2; ER, endoplasmic reticulum; ERGIC, ER–Golgi intermediate compartment (reproduced from Shereen et al. (2020) under a Creative Commons license). b) Different stages of growth and propagation of COVID-19 in human lungs (reproduced from Li et al. (2020b) under a creative commons license).
Fig. 8A cartoon showing the management of COVID-19 with the advisable medicines or preventive measures by social distancing. “X” symbol indicates the prevention the disease and “+” indicates the additional effort required along with social distancing to prevent the disease. Immuno-modulating life style by changing food habit, exercise etc. may be adapted.